Projected US Savings From Biosimilars, 2021–2025

Published in: American Journal of Managed Care, Volume 28, No. 7 (July 2022)

Posted on RAND.org on January 26, 2022

by Andrew W. Mulcahy, Christine Buttorff, Kenneth Finegold, Zeid El-Kilani, Jon F. Oliver, Stephen Murphy, Amber Jessup

Read More

Access further information on this document at www.ajmc.com

This article was published outside of RAND. The full text of the article can be found at the link above.

Substituting biosimilar drugs for biologics could drive down the price of expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025.

Research conducted by

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.